RRX-001 NEW
| Price | $48 | $70 | $117 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-08 |
Product Details
| Product Name: RRX-001 | CAS No.: 925206-65-1 |
| Purity: ≥95% | Supply Ability: 10g |
| Release date: 2025/07/08 |
Product Introduction
Bioactivity
| Name | RRX-001 |
| Description | RRx-001 is a potent inhibitor ofglucose 6-phosphate dehydrogenase(G6PD) and with potent antimalarial activity |
| In vitro | RRx-001 inhibited the growth of colon cancer cells (HCT 116) and decreased levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner. Treatment of HCT 116 cells with 0.5 μM RRx-001 for 24 h significantly increased transcripts of interferon (IFN)-responsive genes and this induction was sustained for up to 4 weeks after transient exposure to RRx-001. RRx-001 increased secretion of type I and III IFNs by HCT 116 cells, and these IFNs were confirmed to be bioactive. Transcription of endogenous retrovirus ERV-Fc2 and LTRs from the ERV-L family (MLT2B4 and MLT1C49) was induced by RRx-001[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (373.11 mM), Sonication is recommended. |
| Keywords | RRx-001 | RRX-001 | RRX001 | RRX 001 | Parasite | Inhibitor | inhibit | G6PD | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Kojic acid | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | Urethane | Hydroxychloroquine | L-Glutamic acid | Doxycycline | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | Anti-Parasitic Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $9.90/10g |
VIP4Y
|
Wuhan Biocar Pharmacy CO.,Ltd.
|
2022-10-21 | |
| $64.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-23 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $7.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-02-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY